NEW YORK (GenomeWeb) – SpeeDx has begun US clinical trials for its Mycoplasma genitalium assay called ResistancePlus MG in anticipation of Food and Drug Administration 510(k) approval for the assay next year.
NEW YORK (GenomeWeb) – SpeeDx has begun US clinical trials for its Mycoplasma genitalium assay called ResistancePlus MG in anticipation of Food and Drug Administration 510(k) approval for the assay next year.
360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.